Latest Articles

Publication Date
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence - OncLive

Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence OncLive

Published: Dec. 5, 2025, 1 p.m.
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy - koreabiomed.com

GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy koreabiomed.com

Published: Dec. 1, 2025, 6:49 a.m.
ZMIZ1 and estrogen receptor α form an essential partnership in endometrial biology.

Estrogen receptor α (ESR1) is a pivotal regulator of endometrial homeostasis and reproductive function, yet the coregulators that fine tune its transcriptional activity remain incompletely defined. In this issue of …

Published: Dec. 1, 2025, midnight
Transcriptional coregulator ZMIZ1 modulates estrogen responses that are essential for healthy endometrial function.

Estrogen is a critical regulator of endometrial health. Aberrant estrogen stimulation can result in infertility, endometrial cancer, and endometriosis. Here, we identified Zinc Finger MIZ-Type Containing 1 (Zmiz1) as a …

Published: Dec. 1, 2025, midnight
Dissecting endometrial cancer complexity in response to standard and targeted therapies - Nature

Dissecting endometrial cancer complexity in response to standard and targeted therapies Nature

Published: Nov. 28, 2025, 5:08 p.m.
Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells - News-Medical

Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells News-Medical

Published: Nov. 27, 2025, 10:29 a.m.
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer - OncLive

DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer OncLive

Published: Nov. 26, 2025, 7:03 p.m.
NICE recommends treatment for primary advanced or recurrent endometrial cancer - Pf Media

NICE recommends treatment for primary advanced or recurrent endometrial cancer Pf Media

Published: Nov. 26, 2025, 4:10 p.m.
Expert explains how weight cycling raises endometrial cancer risk | Tap to know more | Inshorts - Inshorts

Expert explains how weight cycling raises endometrial cancer risk | Tap to know more | Inshorts Inshorts

Published: Nov. 26, 2025, 11:03 a.m.
Network pharmacology prediction of UA in targeting endometriosis progression to endometrial cancer.

Endometriosis is a gynecological disorder predominantly affecting women of reproductive age and is considered a potential risk factor for the development of endometrial cancer. However, the molecular mechanisms underlying the …

Published: Nov. 26, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!